Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-labeled hNd2 (NMK89) PET imaging in MUC5AC-positive pancreatic cancer
NCT06129422Phase 1Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NMK89, sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoints: Adverse Events at 60 days, Physical Examination at 8 days and 4 more. Started Oct 2023; status: completed.
02
Drugs
NMK89
Beyond the preview
Go deeper on NCT06129422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06129422.